Have a feature idea you'd love to see implemented?
Let us know!
BVS Bioventus Inc
Price (delayed)
$11.51
Market cap
$934.09M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.6
Enterprise value
$1.27B
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations
Highlights
Bioventus's EPS has soared by 80% YoY and by 8% from the previous quarter
The company's net income has surged by 78% YoY and by 6% QoQ
The quick ratio has declined by 10% year-on-year but it rose by 7% since the previous quarter
Bioventus's equity has decreased by 16% YoY
Key stats
What are the main financial stats of BVS
Market
Valuations
Earnings
Shares outstanding
81.15M
Market cap
$934.09M
Enterprise value
$1.27B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.27
Price to sales (P/S)
1.35
EV/EBIT
N/A
EV/EBITDA
29.22
EV/Sales
2.3
Revenue
$555.06M
EBIT
-$6M
EBITDA
$43.62M
Free cash flow
$29.05M
Per share
Balance sheet
Liquidity
EPS
-$0.6
Free cash flow per share
$0.45
Book value per share
$1.84
Revenue per share
$8.51
TBVPS
$5.32
Total assets
$769.49M
Total liabilities
$582.66M
Debt
$383.59M
Equity
$148.74M
Working capital
$87.2M
Debt to equity
2.58
Current ratio
1.41
Quick ratio
0.78
Net debt/EBITDA
7.81
Margins
Efficiency
Dividend
EBITDA margin
7.9%
Gross margin
67%
Net margin
-7.1%
Operating margin
-10.2%
Return on assets
-5%
Return on equity
-24.5%
Return on invested capital
-1.2%
Return on capital employed
-1.1%
Return on sales
-1.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BVS stock price
How has the Bioventus stock price performed over time
Intraday
0.88%
1 week
3.41%
1 month
-9.65%
1 year
198.96%
YTD
118.41%
QTD
-3.68%
Financial performance
How have Bioventus's revenue and profit performed over time
Revenue
$555.06M
Gross profit
$371.87M
Operating income
-$56.4M
Net income
-$39.48M
Gross margin
67%
Net margin
-7.1%
BVS's net margin has soared by 80% YoY and by 9% QoQ
The company's net income has surged by 78% YoY and by 6% QoQ
Bioventus's operating margin has surged by 64% YoY and by 9% QoQ
The operating income has soared by 61% YoY and by 7% from the previous quarter
Growth
What is Bioventus's growth rate over time
Valuation
What is Bioventus stock price valuation
P/E
N/A
P/B
6.27
P/S
1.35
EV/EBIT
N/A
EV/EBITDA
29.22
EV/Sales
2.3
Bioventus's EPS has soared by 80% YoY and by 8% from the previous quarter
BVS's price to book (P/B) is 79% more than its last 4 quarters average of 3.5
Bioventus's equity has decreased by 16% YoY
BVS's P/S is 69% above its last 4 quarters average of 0.8
The revenue is up by 10% year-on-year and by 3.4% since the previous quarter
Efficiency
How efficient is Bioventus business performance
Bioventus's ROS has soared by 96% YoY and by 27% from the previous quarter
The return on invested capital has surged by 95% year-on-year and by 25% since the previous quarter
The return on assets has surged by 73% year-on-year and by 3.8% since the previous quarter
The ROE has soared by 71% year-on-year
Dividends
What is BVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BVS.
Financial health
How did Bioventus financials performed over time
Bioventus's total assets is 32% more than its total liabilities
The quick ratio has declined by 10% year-on-year but it rose by 7% since the previous quarter
BVS's current ratio is down by 9% year-on-year but it is up by 6% since the previous quarter
BVS's debt is 158% higher than its equity
Bioventus's equity has decreased by 16% YoY
BVS's debt to equity is up by 16% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.